Rheumatology Network's Top 5: May 28, 2022 - Rheumatology Network

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders. James Woody, MD, PhD, explains… [+503 chars]

full article...